Gynofloran

Gynofloran is a prescription oral medication whose sole active ingredient is fluconazole, an azole antifungal. It is marketed in the European Union and is supplied as tablets for systemic use. Fluconazole works by inhibiting fungal lanosterol 14α‑demethylase, disrupting ergosterol synthesis and compromising the fungal cell membrane. Gynofloran is used under medical supervision for various candidiasis infections, including vaginal, oral, esophageal and systemic candidiasis.

Gynofloran is prescribed for several fungal infections where fluconazole is an appropriate therapy.

- Vulvovaginal candidiasis (yeast infection of the vagina and vulva). - Oropharyngeal and esophageal candidiasis in immunocompromised patients. - Systemic candidiasis affecting bloodstream or internal organs. - Adjunctive treatment of cryptococcal meningitis in combination with other antifungals.

Side effects of Gynofloran vary in frequency; most are mild and reversible, while rare reactions may require medical attention.

Common: - Nausea, abdominal discomfort or dyspepsia. - Headache or dizziness. - Diarrhea or loose stools. - Skin rash or mild itching.

Serious: - Severe allergic reactions such as anaphylaxis. - Liver enzyme elevations indicating possible hepatotoxicity. - QT interval prolongation leading to cardiac arrhythmias. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Gynofloran, clinicians should evaluate patient history and laboratory results to minimize risks.

- Assess liver function; avoid use in patients with severe hepatic impairment. - Review renal function; dose adjustment may be needed in moderate to severe kidney disease. - Caution in patients with known QT prolongation or electrolyte disturbances. - Avoid during pregnancy unless benefits outweigh risks, as safety data are limited. - Monitor for drug interactions, especially with medications metabolized by CYP2C9 and CYP3A4. - Use carefully in patients with a history of allergic reactions to azole antifungals.

Fluconazole can affect the metabolism of many drugs; some combinations should be avoided, while others require dose adjustments.

Avoid: - Concurrent use with cisapride, pimozide, or terfenadine due to risk of serious cardiac events. - Co‑administration with certain statins (e.g., simvastatin, lovastatin) that may cause rhabdomyolysis. - Combining with oral anticoagulants such as warfarin without close INR monitoring.

Use with caution: - Antidiabetic agents (e.g., sulfonylureas, insulin) may need dose reduction to prevent hypoglycemia. - Benzodiazepines (e.g., midazolam, triazolam) may have increased sedation. - Certain immunosuppressants (e.g., cyclosporine, tacrolimus) may require therapeutic drug monitoring. - Oral contraceptives may have reduced efficacy; consider backup contraception.